Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML

Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML

Bibliographic Details
Main Authors:	Jesse M. Tettero, Yara Buisman, Lok Lam Ngai, Costa Bachas, Bjorn T. Gjertsen, Angèle Kelder, Arjan A. van de Loosdrecht, Markus G. Manz, Thomas Pabst, Willemijn Scholten, Gert J. Ossenkoppele, Jacqueline Cloos, David C. de Leeuw
Format:	Article
Language:	English
Published:	Wiley 2023-12-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000981

Similar Items

P448: PROGNOSTIC SIGNIFICANCE OF MEASURABLE RESIDUAL DISEASE DETECTION BY FLOW CYTOMETRY IN AUTOLOGOUS STEM CELL APHERESIS PRODUCTS OF PATIENTS WITH AML
by: Jesse Tettero, et al.
Published: (2023-08-01)

AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML
by: Diana Hanekamp, et al.
Published: (2021-05-01)

MRD Tailored Therapy in AML: What We Have Learned So Far
by: Lok Lam Ngai, et al.
Published: (2021-01-01)

P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.
by: Lok Lam Ngai, et al.
Published: (2023-08-01)

P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL
by: Jesse Tettero, et al.
Published: (2023-08-01)

Early response evaluation in AML using mass cytometry
by: Bjørn T. Gjertsen, et al.
Published: (2019-06-01)

Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis
by: Jesse M. Tettero, et al.
Published: (2022-10-01)

Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.
by: Monique Terwijn, et al.
Published: (2014-01-01)

Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients
by: Veronika Riebl, et al.
Published: (2021-08-01)

Apheresis in Neurological Disorders
by: Johannes Dorst
Published: (2020-10-01)

Maturation State-Specific Alternative Splicing in <i>FLT3</i>-ITD and NPM1 Mutated AML
by: Anna Wojtuszkiewicz, et al.
Published: (2021-08-01)

The Evolving Treatment Landscape of AML
by: Sabine Blum, et al.
Published: (2022-03-01)

MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?
by: Ilias Pessach, et al.
Published: (2022-09-01)

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
by: Jacobien R. Hilberink, et al.
Published: (2023-06-01)

Therapeutic apheresis in autoimmune diseases
by: Bambauer R, et al.
Published: (2013-11-01)

Apheresis platelets in additive solution: Is it a good alternative to conventional group-specific apheresis platelets?
by: Amit Agrawal
Published: (2017-01-01)

Autologous Transplantation for Older Adults with AML
by: Beatrice U. Mueller, et al.
Published: (2018-09-01)

Apheresis in Autoimmune Encephalitis and Autoimmune Dementia
by: Rosa Rössling, et al.
Published: (2020-08-01)

Therapeutic apheresis in hematopoietic cell transplantation
by: Paul Höcker, et al.
Published: (2008-12-01)

Role of therapeutic apheresis in pediatric disorders
by: Rekha Hans, et al.
Published: (2016-10-01)

Leukocyte apheresis in the management of ulcerative colitis
by: Helmy Ahmed, et al.
Published: (2009-01-01)

Haematological Changes in Donors Post Apheresis
by: Nikhil, et al.
Published: (2021-07-01)

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
by: Jesse M. Tettero, et al.
Published: (2022-01-01)

BCL-2 inhibitor and conventional chemotherapy combinations for acute myeloid leukemia: shifting from the unfit to the fit patient with AML
by: Ossenkoppele, G, et al.
Published: (2020)

The effect of DALI lipid apheresis in the prognosis of homozygous familial hypercholesterolemia: Seven patients' experience at a DALI apheresis center
by: Muhammet Bulut, et al.
Published: (2020-01-01)

P1387: TREATMENT WITH A LEUKEMIA-DERIVED DENDRITIC CELL VACCINE INDUCES INNATE AND ADAPTIVE IMMUNE RESPONSE CORRELATING WITH CLINICAL RESPONSE IN AML PATIENTS IN CR1 WITH MEASURABLE RESIDUAL DISEASE
by: Hester van Zeeburg, et al.
Published: (2023-08-01)

Gene expression profiles associated with pediatric relapsed AML.
by: Costa Bachas, et al.
Published: (2015-01-01)

Polyzwitterionic Coating of Porous Adsorbents for Therapeutic Apheresis
by: Vladislav Semak, et al.
Published: (2022-11-01)

LIPOPROTEIN APHERESIS: YESTERDAY, TODAY, TOMORROW. REVIEW
by: U. Julius, et al.
Published: (2018-09-01)

Therapeutic apheresis in kidney diseases: an updated review
by: Yi-Yuan Chen, et al.
Published: (2022-12-01)

Machine and man individualities in apheresis adverse events
by: Sudipta Sekhar Das, et al.
Published: (2018-01-01)

Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia
by: Minichilli Fabrizio, et al.
Published: (2011-10-01)

Role of lipoprotein apheresis in the management of familial hypercholesterolemia
by: Shamanna Seshadri Iyengar, et al.
Published: (2021-01-01)

Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
by: Jeroen Janssen, et al.
Published: (2021-02-01)

Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients
by: Bianca R. Schnell, et al.
Published: (2019-04-01)

Thromboelastography as a tool for quality check of apheresis platelets
by: Anupam Verma, et al.
Published: (2016-01-01)

Therapeutic Apheresis in Glomerular Diseases after Kidney Transplantation
by: Maurizio Salvadori, et al.
Published: (2020-05-01)

Recovery of Platelet Count among Apheresis Platelet Donors
by: Ravindra Prasad Thokala, et al.
Published: (2016-12-01)

Lipoprotein apheresis to treat elevated lipoprotein (a)1
by: Elisa Waldmann, et al.
Published: (2016-10-01)

REVIEW OF NEW INDICATIONS – JOURNAL OF CLINICAL APHERESIS PERSPECTIVE
by: Huy Pham
Published: (2021-11-01)